electroCore,

electroCore, FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of electroCore, (ECOR) as of Oct 18, 2026 is 59.09 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 58.46 % — a change of 1.09% (higher).

FCF Conversion

59.09 %

YoY

1.09%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of electroCore, is 2025 59.09 % . FCF Conversion Rate (FCF/EBITDA) of electroCore, was 2024 58.46 % . It decreases by 1.09% higher compared to the previous year.

The electroCore, FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
84.90 USD
Jan 1, 2019
99.97 USD
Jan 1, 2020
85.28 USD
Jan 1, 2021
79.14 USD
Jan 1, 2022
75.11 USD
Jan 1, 2023
78.97 USD
Jan 1, 2024
58.46 USD
Jan 1, 2025
59.09 USD
The electroCore, FCF Conversion history
YEARFCF ConversionYoY
59.09 %+1.09%
58.46 %-25.98%
78.97 %+5.15%
75.11 %-5.10%
79.14 %-7.20%
85.28 %-14.70%
99.97 %+17.76%
84.90 %+19.25%
71.19 %-16.25%
85.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

FCF Conversion Rate (FCF/EBITDA) of electroCore, is 59.09 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of electroCore, changed from 58.46 % to 59.09 %, representing a 1.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) electroCore, since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s electroCore, with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — electroCore,

All Key Metrics — electroCore,